New drug shows promise against rare liver infection
Disease control
Ongoing
This Phase 2 trial tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of hepalatide daily for 48 weeks, or delayed treatment. The main goal is to see if the drug can lower the v…
Phase: PHASE2 • Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC